|
3rd Feb 12 - Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland. PCV13 is the most cost-effective option if the analysis is based on a serotype distribution reflecting 2011 data. download document |
|
19th Jan 12 - Telaprevir (Incivo®) We consider telaprevir a highly cost-effective therapy when added to peginterferon-ribavirin for the treatment of patients infected with genotype 1 hepatitis C virus in the Irish healthcare setting. download document |
|
17th Jan 12 - Boceprevir (Victrelis®) We consider boceprevir a highly cost-effective therapy when added to peginterferon-ribavirin for the treatment of patients infected with genotype 1 hepatitis C virus in the Irish healthcare setting. download document |
|
8th Dec 11 - Denosumab (XGEVA®) We consider denosumab (XGEVA®) a cost-effective therapy for the prevention of skeletal-related events in adults with bone metastases from solid tumours in the Irish healthcare setting. download document |
|
11th Oct 11 - Ticagrelor (Brilique®) We consider Ticagrelor (Brilique®) a cost effective therapy for the prevention of atherothrombotic events in adult patients with ACS including patients managed medically and those managed with PCI or CABG. download document |
|
3rd Oct 11 - Oncotype DX® Following a price revision the NCPE now consider Oncotype DX a cost-effective therapy to target chemotherapy use in lymph-node-negative, oestrogen-receptor-positive, early-stage breast cancer in Ireland. |
|
22nd Sep 11 - Fingolimod (Gilenya®) Following a price revision we now consider FIngolimod (Gilenya®) a cost-effective therapy for the treatment of relapsing-remitting multiple sclerosis patients in the Irish healthcare setting. |
|
20th Sep 11 - Fingolimod (Gilenya®) for the 2nd line treatment of highly active relapsing-remitting multiple sclerosis. We do not recommend the reimbursement of Fingolimod at the submitted price. download document |
|
6th Sep 11 - Aztreonam 75mg powder and solvent for nebuliser solution (Cayston®) for chronic PA in cystic fibrosis patients. Whilst there may be a role for aztreonam (Cayston®) the Company submission does not justify the price premium requested. download document |
|
6th Sep 11 - Ipilimumab (Yervoy®) for the treatment of advanced melanoma in adults who received prior therapy. We cannot recommend reimbursement of ipilimumab at the submitted price. download document |
|
9th Aug 11 - Dabigatran etexilate (Pradaxa®) for the prevention of stroke and systemic embolism in atrial fibrillation. We do not recommend the reimbursement of dabigatran at the submitted price. download document |
|
19th Jul 11 - NCPE assessment of Oncotype DX® to target chemotherapy use in LN-, ER+ early stage breast cancer. We do not recommend the reimbursement of Oncotype DX® at the submitted price. download document |
|
4th May 11 - Vernakalant (Brinavess®) for the treatment of haemodynamically stable, symptomatic patients with atrial fibrillation of less than 48 hours duration. Following review, we recommend reimbursement of vernakalant in the hospital setting. download document |
|
13th Apr 11 - NCPE assessment of oral tapentadol (Palexia®) for adult patients with severe chronic/acute pain. Tapentadol (Palexia®) may be considered cost-effective but should be reserved for patients who cannot tolerate existing strong oral opioids. download document |
|
24th Mar 11 - Prucalopride (Resolor®) to be reimbursed under the Community Drugs Schemes. Prucalopride (Resolor®) is to be reimbursed under the Community Drugs Schemes subject to conditions. download document |
|
12th Nov 10 - Reimbursement of certolizumab pegol (Cimzia®) under the High Tech Drug Scheme. Following a negative assessment on 01/09/2010 Cimzia® is now reimbursed following a reduction in cost to the HSE through a patient access scheme and a price revision. |
|
5th Nov 10 - NCPE review of oral gefitinib (Iressa®) for the treatment of locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR. We do not recommend the reimbursement of gefitinib for first line therapy on the High Tech Drug Scheme. However, it may be considered for second line therapy. download document |
|
4th Nov 10 - NCPE reivew of eltrombopag (Revolade®) for the treatment of chronic immune thrombocytopenia (ITP). The review group do not recommend the reimbursement of eltrombopag (Revolade®)under the High Tech Drug scheme. download document |
|
3rd Nov 10 - Review of the cost-effectiveness of Roflumilast (Daxas®) for the maintenance treatment of severe COPD. We do not recommend reimbursement of Roflumilast (Daxas®) under the the Community Drugs Schemes. download document |
|
19th Oct 10 - Review of oral oxycodone/naloxone prolonged release tablet (Targin®). Following a price revision oxycodone/naloxone (Targin®) is now reimbursed under the Community Drugs Schemes. Our original assessment was completed on 13/07/2010. |
|
1st Sep 10 - NCPE review of the cost-effectiveness of certolizumab pegol (Cimzia®) for the treatment of moderate to severe rheumatoid arthritis. We do not recommend reimbursement of certolizumab pegol (Cimzia®) under the Community Drugs Schemes at the proposed price. download document |
|
15th Jul 10 - NCPE review of the cost-effectiveness of denosumab (Prolia®). We consider denosumab a cost-effective therapy for the prevention of osteoporotic fractures in postmenopausal women in the Irish heathcare setting. download document |
|
13th Jul 10 - New template for rapid review assessment submissions from manufacturers. Our new template for the rapid review process is to be found in the section "Pharmacoeconomic Guidelines". |
|
13th Jul 10 - NCPE review of the cost-effectiveness of oral oxycodone/naloxone prolonged release tablet (Targin®). We do not recommend reimbursement of oxycodone/naloxone (Targin®) under the Community Drugs Schemes at the proposed price. download document |
|
13th Jul 10 - Mifamurtide (Meptact®) for the treatment of osteosarcoma. A formal PEA is required to demonstrate value for money prior to reimbursement. |
|
22nd Jun 10 - Rapid review of Ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukaemia (CLL). We believe a formal PEA will be required to demonstrate value for money prior to reimbursement. |
|
2nd Jun 10 - NCPE review of the cost-effectiveness of golimumab (Simponi®) for the treatment of moderate to severe rheumatoid arthritis. Following a revision in price we consider golimumab a cost-effective option for the treatment of rheumatoid arthritis in the Irish Healthcare setting. download document |
|
11th May 10 - NCPE evaluation of the cost effectiveness of golimumab (Simponi®) for the treatment of moderate to severe rheumatoid arthritis. The reveiw group do not consider golimumab cost-effective at the submitted price. download document |
|
5th Mar 10 - Economic Evaluation of Eculizumab (Soliris®) for the treatment of paroxysmal noctural haemoglobinuria (PNH). Alexion Pharma UK. Ltd have failed to demonstrate the cost-effectiveness of eculizumab for the treatment of PNH in the Irish healthcare setting. download document |
|
1st Feb 10 - Economic Evaluation of Prasugrel (Efient®) for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention. The review group consider that prasugrel, co-administered with aspirin, is cost-effective in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention in the Irish healthcare setting. download document |
|
15th Jan 10 - NCPE review of Indacaterol (Onbrez®) for the treatment of COPD It is recommended that Indacaterol (Onbrez®) should not be subjected to a PEA at this time. |
|
15th Jan 10 - NCPE evaluation of the cost-effectiveness of the rotavirus vaccine. NCPE completed the evaluation of the cost-effectiveness of a universal rotavirus vaccination programme in Ireland, on behalf of the National Immunisation Advisory Committee (NIAC). A summary of the main findings are available in the attached document: download document |
|
12th Jan 10 - NCPE Review of Dronedarone (Multaq®) for the treatment of current non-permanent atrial fibrillation. It is recommended that dronedarone should not under PEA at this time. |
|
11th Dec 09 - NCPE evaluation of agomelatine (Valdoxan®) for the treatment of major depressive disorder. Following a revision in price application we now consider agomelatine (Valdoxan®) cost effective under the Community Drugs schemes. The product will now be added to the list of items reimbursable under the schemes. |
|
8th Dec 09 - Cost effectiveness of Ustekinumab (Stelara®) for the treatment of moderate to severe plaque psoriasis. We consider ustekinumab cost effective for the treatment of moderate to severe plaque psoriasis in the Irish healthcare setting. download document |
|
8th Dec 09 - NCPE review of Adenuric (Febuxostat®) a xanthine oxidase inhibitor for the treatment of gout. It is recommended that Adenuric (Febuxostat®) should not be subjected to PEA at this time. |
|
19th Nov 09 - NCPE review of Ranolazine (Ranexa®) a late sodium channel inhibitor for the treatment of angina pectoris. We recommend that Ranolazine should not undergo PEA at this time. |
|
15th Oct 09 - NCPE Review of degarelix (Firmagon®) a GnRH antagonist for the treatment of prostate cancer. Following review it was recommended that degarelix should not be subjected to PEA at this time. |
|
7th Oct 09 - NCPE Review of Liraglutide (Victoza®) for the treatment of adults with type 2 diabetes mellitus. Following review it was recommended that Liraglutide should not be subjected to PEA at this time. |
|
3rd Sep 09 - NCPE evaluation of agomelatine (Valdoxan®) for the treatment of major depressive disorder. At the current price agomelatine (Valdoxan®) is not considered cost-effective for the treatment of major depressive episodes under the Community Drugs Schemes. download document |
|
18th Jun 09 - NCPE evaluation of sapropterin (Kuvan®) for the treatment of phenylketonuria (PKU). Sapropterin (Kuvan®) is not a cost effective treatment for patients with phenylketonuria. download document |
|
17th Jun 09 - Health technology assessment (HTA) of a population-based colorectal cancer screening programme in Ireland. This HTA was prepared by the National Cancer Registry Ireland, the National Centre for Pharmacoeconomics, the School for Health & Related Research, Sheffield University and Dublin City University. It is available on the HIQA website. Related Link |
|
16th Jun 09 - NCPE evaluation of the cost effectiveness of glucosamine sulfate (DONA®) for the treatment of osteoarthritis. We do not believe that glucosamine sulfate (DONA®) is a cost effective therapy for the treatment of osteoarthritis in the Irish Healthcare setting. download document |
|
2nd Jun 09 - NCPE evaluation of the impact of the post-patent price cut on medicines following the 2006 IPHA-HSE Agreement. Total savings on the GMS,DP and LTI schemes were estimated at €248.5 million. download document |
|
6th Feb 09 - NCPE reports on the cost-effectiveness of ambrisentan (Volibris®) in the treatment of patients with Functional Class II or III pulmonary arterial hypertension. A summary of the main findings are included in the attached document. download document |